Keegan P - Search Results

1

Overview of Oncology and Hematology Drug Approvals at US Food and Drug Administration Between 2008 and 2016.

Zhou J, Vallejo J, Kluetz P, Pazdur R, Kim T, Keegan P, Farrell A, Beaver JA, Sridhara R. Zhou J, et al. Among authors: keegan p. J Natl Cancer Inst. 2019 May 1;111(5):449-458. doi: 10.1093/jnci/djy130. J Natl Cancer Inst. 2019. PMID: 30085269 Review.

2

Accelerated approval of oncology products: a decade of experience.

Dagher R, Johnson J, Williams G, Keegan P, Pazdur R. Dagher R, et al. Among authors: keegan p. J Natl Cancer Inst. 2004 Oct 20;96(20):1500-9. doi: 10.1093/jnci/djh279. J Natl Cancer Inst. 2004. PMID: 15494600 Review.

3

Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007.

Sridhara R, Johnson JR, Justice R, Keegan P, Chakravarty A, Pazdur R. Sridhara R, et al. Among authors: keegan p. J Natl Cancer Inst. 2010 Feb 24;102(4):230-43. doi: 10.1093/jnci/djp515. Epub 2010 Jan 29. J Natl Cancer Inst. 2010. PMID: 20118413 Review.

4

Accelerated approval of oncology products: the food and drug administration experience.

Johnson JR, Ning YM, Farrell A, Justice R, Keegan P, Pazdur R. Johnson JR, et al. Among authors: keegan p. J Natl Cancer Inst. 2011 Apr 20;103(8):636-44. doi: 10.1093/jnci/djr062. Epub 2011 Mar 21. J Natl Cancer Inst. 2011. PMID: 21422403 Review.

5

Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy: A Report From the US Food and Drug Administration.

Kazandjian D, Khozin S, Blumenthal G, Zhang L, Tang S, Libeg M, Kluetz P, Sridhara R, Keegan P, Pazdur R. Kazandjian D, et al. Among authors: keegan p. JAMA Oncol. 2016 Jan;2(1):118-22. doi: 10.1001/jamaoncol.2015.3934. JAMA Oncol. 2016. PMID: 26470053 Clinical Trial.

6

Expansion Cohorts in First-in-Human Solid Tumor Oncology Trials.

Theoret MR, Pai-Scherf LH, Chuk MK, Prowell TM, Balasubramaniam S, Kim T, Kim G, Kluetz PG, Keegan P, Pazdur R. Theoret MR, et al. Among authors: keegan p. Clin Cancer Res. 2015 Oct 15;21(20):4545-51. doi: 10.1158/1078-0432.CCR-14-3244. Clin Cancer Res. 2015. PMID: 26473190

7

A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review.

Beaver JA, Howie LJ, Pelosof L, Kim T, Liu J, Goldberg KB, Sridhara R, Blumenthal GM, Farrell AT, Keegan P, Pazdur R, Kluetz PG. Beaver JA, et al. Among authors: keegan p. JAMA Oncol. 2018 Jun 1;4(6):849-856. doi: 10.1001/jamaoncol.2017.5618. JAMA Oncol. 2018. PMID: 29494733 Review.

8

Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs.

Kim J, Nair A, Keegan P, Beaver JA, Kluetz PG, Pazdur R, Chuk M, Blumenthal GM. Kim J, et al. Among authors: keegan p. Oncologist. 2020 Apr;25(4):348-354. doi: 10.1634/theoncologist.2019-0653. Epub 2019 Dec 17. Oncologist. 2020. PMID: 32297444 Free PMC article.

9

FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer.

Cohen MH, Gootenberg J, Keegan P, Pazdur R. Cohen MH, et al. Among authors: keegan p. Oncologist. 2007 Mar;12(3):356-61. doi: 10.1634/theoncologist.12-3-356. Oncologist. 2007. PMID: 17405901 Free article. Clinical Trial.

10

FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.

Cohen MH, Gootenberg J, Keegan P, Pazdur R. Cohen MH, et al. Among authors: keegan p. Oncologist. 2007 Jun;12(6):713-8. doi: 10.1634/theoncologist.12-6-713. Oncologist. 2007. PMID: 17602060 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

186 results

Search Page

Filters